About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

NCT04980248·4 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Alexion Pharmaceuticals, Inc.

Age

18–64

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Confirmed clinical diagnosis of HPP
Not anticipated to require further treatment with enzyme replacement therapy to treat participant's HPP after study completion
Willing and able to follow protocol-specified contraception requirements
Willing and able to give informed consent

You may not be if

Primary or secondary hyperparathyroidism or hypoparathyroidism
Fracture within 12 weeks of screening
Current or relevant history of unstable physical or psychiatric illness
Significant allergies
Asfotase alfa use within 6 months and/or positive for asfotase alfa antidrug antibody/neutralizing antibodies

The record

StatusCompleted

PhasePhase 1

Taking part15

StartedSep 2021

UpdatedDec 27, 2024

Conditions

Hypophosphatasia

Where4

Research Site
Las Vegas, Nevada, United States
Research Site
Columbus, Ohio, United States
Research Site
Nashville, Tennessee, United States

Clareo Health | Study of ALXN1850 in Participants With Hypophosphatasia (HPP)